You are here: Industry Insights > Gannex

News List

Gannex Announces Completion of the U.S. Phase I Trial of ASC43F, an In-House Developed First-in-Class Dual Targeting Fixed-dose Combination Tablet for NASH prnasia
January 04, 2022
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces the completion of the U.S. Phase I trial of ASC43F, an in-house developed...
Gannex Announces Clinical and Preclinical Data of Four NASH Programs to be Presented in Oral or Poster Presentation at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases prnasia
October 14, 2021
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672), announces today that the latest clinical and preclinical data of four NASH programs...
Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China prnasia
July 13, 2021
Ascletis Pharma Inc. today announces the dosing of the first cohort of healthy subjects in the ASC42 bridging study in China for CHB indication.
Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist prnasia
June 17, 2021
Gannex announces positive topline results of safety and pharmacodynamic biomarkers from the U.S. Phase I trial of NASH drug farnesoid X receptor (FXR) agonist ASC42.
Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication prnasia
May 27, 2021
Gannex today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for NASH indication.
Gannex Announces the First Cohort Dosed in a U.S. Clinical Study with THR-β Agonist ASC41 prnasia
April 15, 2021
Gannex, a wholly owned company of Ascletis Pharma Inc., fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), announces the dosing of the first cohort in the U.S. Phase I clinical study of ...
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH prnasia
March 09, 2021
Gannex Pharma Co., Ltd., a wholly-owned company of Ascletis Pharma Inc., and Sagimet Biosciences Inc. jointly announced today positive topline results from the China cohort of a Phase 2 randomized, placebo-controlled clinical trial of oral ...
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41 prnasia
February 22, 2021
Gannex announces the positive clinical results in overweight and obese subjects for ASC41, a liver-targeted prodrug. The active metabolite of ASC41 is a selective thyroid hormone receptor beta (THR-β) agonist.
Gannex Announces Positive Phase I Clinical Results on Its THR-β Agonist ASC41 prnasia
January 12, 2021
Gannex, a wholly owned company of Ascletis Pharma Inc. and fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces the positive phase I clinical results of ASC41 oral tablet ...
First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial prnasia
December 28, 2020
Gannex announces today dosing of first subject with its NASH drug candidate ASC42, a Farnesoid X Receptor (FXR) agonist, in a U.S. Phase I Trial.

Previous page 1 2 Next page